Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

AdaptHealth Lowers FY2025 Sales Guidance From $3.22B-$3.36B To $3.18B-$3.32B Vs $3.27B Est; Sees Adjusted EBITDA Of $665M To $705M (Prior $670M To $710M)

Author: Benzinga Newsdesk | May 06, 2025 06:10am

Financial Outlook

The Company is updating previous financial guidance for fiscal year 2025 to account for the disposition of certain incontinence assets, as follows:

Net revenue of $3.18 billion to $3.32 billion, from $3.22 billion to $3.36 billion
Adjusted EBITDA of $665 million to $705 million, from $670 million to $710 million
Free cash flow of $180 million to $220 million, unchanged

Posted In: AHCO